HoxA10 Antibody (C-2): sc-271953

HoxA10 Antibody (C-2) is a mouse monoclonal IgM antibody that detects HoxA10 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). HoxA10 is a crucial transcriptional regulator belonging to the Abdominal B (AbdB) homeobox subfamily, playing a significant role in embryonic development and reproductive processes. HoxA10 is primarily located in the developing genitourinary tract and adult uterus, where HoxA10 expression is tightly regulated throughout the menstrual cycle. Notably, HoxA10 expression increases during the midsecretory phase, correlating with elevated progesterone levels, which is essential for preparing the endometrium for potential implantation. HoxA10′s ability to respond to hormonal changes is vital for reproductive health, as evidenced by HoxA10′s concentration-dependent increase in cultured endometrial cells upon progesterone stimulation, a response that can be inhibited by the progesterone receptor antagonist RU486. Furthermore, the differential expression of HoxA10 in the myometrium throughout the menstrual cycle highlights HoxA10′s importance in uterine function. In cases of endometriosis, a condition characterized by abnormal tissue growth, the lack of a mid-luteal increase in HoxA10 expression may contribute to the pathology, underscoring HoxA10′s critical role in reproductive health and disease. Anti-HoxA10 antibody (C-2) is an invaluable tool for researchers investigating the molecular mechanisms underlying these processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HoxA10 Antibody (C-2) References:

1. HoxA10 influences protein ubiquitination by activating transcription of ARIH2, the gene encoding Triad1.  |  Wang, H., et al. 2011. J Biol Chem. 286: 16832-45. PMID: 21454682
2. Upregulation HOXA10 homeobox gene in endometrial cancer: role in cell cycle regulation.  |  Zhang, L., et al. 2014. Med Oncol. 31: 52. PMID: 24943991
3. Hoxa10 null animals exhibit reduced platelet biogenesis.  |  Konieczna, IM., et al. 2016. Br J Haematol. 173: 303-13. PMID: 26847476
4. Aberrant HOXA10 Methylation in Patients With Common Gynecologic Disorders: Implications for Reproductive Outcomes.  |  Kulp, JL., et al. 2016. Reprod Sci. 23: 455-63. PMID: 26865543
5. HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway.  |  Chen, W., et al. 2019. Cancer Manag Res. 11: 6625-6635. PMID: 31406476
6. HOXA10 promotes the development of bladder cancer through regulating FOSL1.  |  Cui, YP., et al. 2020. Eur Rev Med Pharmacol Sci. 24: 2945-2954. PMID: 32271412
7. Loss of HOXA10 causes endometrial hyperplasia progressing to endometrial cancer.  |  Mishra, A., et al. 2022. J Mol Endocrinol. 69: 431-444. PMID: 35917434
8. HOXA10 Expressing UCMSCs Transplantation Improved Endometrial Receptivity on Endometrial Injury.  |  Wu, M., et al. 2023. Curr Stem Cell Res Ther. 18: 1001-1012. PMID: 36121094
9. HOXA10 enhances cell proliferation and suppresses apoptosis in esophageal cancer via activating p38/ERK signaling pathway.  |  Jiang, L. and Yang, Q. 2022. Open Med (Wars). 17: 1750-1759. PMID: 36407869
10. LncRNA HOXA10-AS promotes the progression of esophageal carcinoma by regulating the expression of HOXA10.  |  Kuai, J., et al. 2023. Cell Cycle. 22: 276-290. PMID: 36588458

The preferred HoxA10 antibody is HoxA10 Antibody (E-11): sc-271428.